Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Metformin in Insulin Resistant Left Ventricular (LV) Dysfunction, a Double-Blind, Placebo-Controlled Trial (TAYSIDE Trial)
This study is currently recruiting participants.
Verified by University of Dundee, June 2008
Sponsored by: University of Dundee
Information provided by: University of Dundee
ClinicalTrials.gov Identifier: NCT00473876
  Purpose

Will metformin improve exercise capacity in chronic heart failure patients who has insulin resistance (pre-diabetic- means before they become diabetic)?


Condition Intervention Phase
Congestive Heart Failure
Insulin Resistance
Drug: Metformin
Drug: Matched Placebo (Capsules)
Phase IV

MedlinePlus related topics: Exercise and Physical Fitness Heart Failure
Drug Information available for: Insulin Metformin Metformin hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Metformin in Insulin Resistant LV Dysfunction, a Double-Blind, Placebo-Controlled Trial (TAYSIDE Trial)

Further study details as provided by University of Dundee:

Primary Outcome Measures:
  • Exercise capacity before and after 4 months of intervention [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Possible mechanisms that can explain the improvement of exercise capacity [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 66
Study Start Date: August 2007
Estimated Study Completion Date: April 2009
Estimated Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
Receiving Metformin for 4 months
Drug: Metformin
Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
2: Placebo Comparator
Matched Placebo for 4 months
Drug: Matched Placebo (Capsules)
Similar dosing regime as active comparator

Detailed Description:

Exercise incapacity is one of the major debilitating symptoms of heart failure patients. Studies showed that heart failure patients will become insulin resistance (IR) or vice versa, severity of heart failure also correlates with the severity of insulin resistance. A recent study demonstrated that if we correct diabetic patient insulin resistance by giving them a drug to make them more sensitive to the effects of insulin, their exercise capacity improves. Therefore, we think that the same effects might happen in heart failure patients who have been identified to the insulin resistance by blood test. Insulin resistance means that they have not yet become diabetic and it is a stage the diabetic patients go through before they develop diabetes.

Therefore, we plan to use a drug called metformin (a diabetic drug), give it to heart failure patients who also have IR for 4 months and examine the effects before and after 4 months of treatment. It is a double blind control study, therefore, neither the examiner nor the patient know which drug they receive (either active drug- Metformin, or a placebo).

The main objective is to assess their exercise capacity using an exercise test called Innocor System. It is a bicycle based exercise test that involves patient breathing into a mouth piece before and during exercise in order for the machine to work out the maximum oxygen consumption and pumping power of the heart.

The other objectives of the trial are looking at the possible mechanisms of improving exercise capacity. We aim to answer the following questions by doing the following tests:

Does exercise capacity improve because of

  1. The effect of metformin on the heart? We will answer this question by doing an ultrasound scan of the heart (Echocardiography)
  2. The effects on the blood vessels? We plan to perform a test called flow-mediated dilatation, it is an ultrasound scan of the artery in the arm and also assess the blood flow in the skin using a test called Laser Doppler scan (small amount of medication will be delivered through a small electric current and the blood vessels response will be assessed using the laser doppler scan)
  3. The effects on the muscle? We will do a muscle biopsy looking at the enzymes activities in the muscle before and after taking 4 months of medication.
  Eligibility

Ages Eligible for Study:   25 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged 25-80 yrs with compensated CHF in NYHA functional II-III with evidence of insulin resistance [fasting insulin resistance index values of > 2.7 are said to have insulin resistance].
  • Left ventricular dysfunction. LV ejection fraction < 35%

Exclusion Criteria:

  • Elderly patients (aged >80 yrs);
  • Patients with decompensated CHF (NYHA functional class IV and /or signs of decompensated CHF);
  • Renal dysfunction (serum creatinine > 160 mmol/L);
  • Patients who are unable to exercise including patients that will be excluded for reasons of safety or potential effects on exercise performance. Therefore, patients with angina or other cardiac or pulmonary symptoms potentially limiting exercise performance will be excluded.
  • Systolic blood pressure >190 mmHg at rest or >250 mmHg with exercise or diastolic blood pressure >95 mmHg at rest or >105 mmHg with exercise will also be a reason for exclusion;
  • Patients with underlying disease likely to limit life span and/or increase risk of interventions will be excluded i.e., cancer; cardiovascular disease .i.e., uncontrolled hypertension: SBP>180 mmHg or DBP, recent stroke, any severe chronic disease (including renal and hepatic disease).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00473876

Contacts
Contact: Aaron K Wong, MBChB, MRCP 0044(0)1382660111 ext 33176 a.k.f.wong@dundee.ac.uk
Contact: Chim C Lang, FRCP 0044(0)1382660111 c.c.lang@dundee.ac.uk

Locations
United Kingdom, Scotland
Medicine and Therapeutics, Ninewells Hospital Recruiting
Dundee, Scotland, United Kingdom, DD1 9SY
Sponsors and Collaborators
University of Dundee
Investigators
Principal Investigator: Chim Lang, MD, FRCP University of Dundee, Scotland
  More Information

Responsible Party: University of Dundee ( Dr Aaron KF Wong )
Study ID Numbers: WON001
Study First Received: May 15, 2007
Last Updated: June 10, 2008
ClinicalTrials.gov Identifier: NCT00473876  
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by University of Dundee:
Chronic Heart Failure
Insulin Resistance
Metformin
Peak VO2

Study placed in the following topic categories:
Hyperinsulinism
Heart Failure
Metabolic Diseases
Heart Diseases
Metformin
Insulin Resistance
Metabolic disorder
Glucose Metabolism Disorders
Insulin

Additional relevant MeSH terms:
Hypoglycemic Agents
Physiological Effects of Drugs
Cardiovascular Diseases
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009